Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1152/japplphysiol.01386.2003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Effect of Anti-Activin Receptor Type IIA and Type IIB Antibody on Muscle, Bone and Blood in Healthy and Osteosarcopenic Mice.
J Cachexia Sarcopenia Muscle
February 2025
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Background: Anti-Activin Receptor Type IIA and Type IIB antibody (αActRIIA/IIB ab) is a recently developed drug class that targets the activin receptor signalling pathway. Inhibition of receptor ligands (activins, myostatin, growth differentiation factor 11, etc.) can lead to skeletal muscle hypertrophy, bone formation, and increased haematopoiesis.
View Article and Find Full Text PDFA non-conditioned bone marrow transplantation mouse model to study clonal hematopoiesis and myeloid malignancies.
Exp Hematol Oncol
January 2025
Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood or bone marrow cells carry mutations associated with hematological malignancies. Individuals with CHIP have an increased risk of developing hematological malignancies, atherosclerotic cardiovascular disease, and all-cause mortality. Bone marrow transplantation (BMT) of cells carrying CHIP mutations into irradiated mice are useful procedures to investigate the dynamics of clonal expansion and potential therapeutic strategies, but myeloablative conditioning can induce confounding effects.
View Article and Find Full Text PDFGATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome.
Blood Cancer J
January 2025
Université de Toulouse 3 Paul Sabatier, Cancer Research Centre of Toulouse, UMR1037 Inserm, UMR5077 CNRS, Equipe Labellisée Ligue Nationale Contre le Cancer 2023, Equipe labélisée Institut Carnot Opale, 31037, Toulouse, France.
GATA2 germline mutations lead to a syndrome characterized by immunodeficiency, vascular disorders and myeloid malignancies. To elucidate how these mutations affect hematopoietic homeostasis, we created a knock-in mouse model expressing the recurrent Gata2 R396Q missense mutation. Employing molecular and functional approaches, we investigated the mutation's impact on hematopoiesis, revealing significant alterations in the hematopoietic stem and progenitor (HSPC) compartment in young age.
View Article and Find Full Text PDFRedox biomarker levels in patients with myelodysplastic syndrome.
Biomed Rep
March 2025
Department of Biochemistry and Biotechnology, University of Thessaly, Viopolis, Mezourlo, Larissa 41500, Greece.
Myelodysplastic syndrome (MDS) is a heterogeneous clonal disorder characterized by insufficient hematopoiesis, peripheral blood cytopenia and an increased risk for malignant transformation to acute myeloid leukemia. Several factors, such as age, sex and lifestyle, promote the development of MDS syndrome. Oxidative stress, along with its detrimental effects, cause hematological disorders; however, its role in the pathogenesis of MDS is unknown.
View Article and Find Full Text PDFEpstein-Barr Virus-Induced 3 Attributes to TLR7-Mediated Splenomegaly.
Immunology
January 2025
Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Japan.
Epstein-Barr virus-induced 3 (EBI3) functions as a component of the heterodimer cytokine IL-27, which regulates innate and acquired immune responses. The expression of EBI3 gene is induced by Toll-like receptors (TLRs). Repeated treatment with imiquimod (IMQ), a TLR7 agonist, induces splenomegaly and cytopaenia due to increased splenic function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!